Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls.
Source: International Pharmaceutical Regulatory Monitor
Wockhardt is in hot water with the FDA again, receiving another warning letter for significant GMP violations regarding quality and data controls.
Source: International Pharmaceutical Regulatory Monitor